Kayne Anderson Rudnick Investment Management
CRL icon

Kayne Anderson Rudnick Investment Management’s Charles River Laboratories CRL Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$13.7K Sell
90
-1,950,183
-100% -$296M ﹤0.01% 698
2025
Q1
$294M Buy
1,950,273
+144,732
+8% +$21.8M 0.72% 49
2024
Q4
$333M Sell
1,805,541
-134,284
-7% -$24.8M 0.77% 49
2024
Q3
$382M Buy
1,939,825
+30,836
+2% +$6.07M 0.84% 45
2024
Q2
$394M Buy
1,908,989
+31,359
+2% +$6.48M 0.96% 38
2024
Q1
$509M Buy
1,877,630
+124,392
+7% +$33.7M 1.18% 26
2023
Q4
$414M Buy
1,753,238
+7,137
+0.4% +$1.69M 1.04% 35
2023
Q3
$342M Buy
1,746,101
+64,981
+4% +$12.7M 0.98% 38
2023
Q2
$353M Buy
1,681,120
+52,757
+3% +$11.1M 0.99% 36
2023
Q1
$329M Buy
1,628,363
+11,563
+0.7% +$2.33M 0.97% 39
2022
Q4
$352M Sell
1,616,800
-15,461
-0.9% -$3.37M 1.1% 33
2022
Q3
$321M Buy
1,632,261
+22,434
+1% +$4.42M 1.07% 30
2022
Q2
$344M Sell
1,609,827
-28,856
-2% -$6.17M 1.09% 30
2022
Q1
$465M Buy
1,638,683
+86,028
+6% +$24.4M 1.24% 24
2021
Q4
$585M Buy
1,552,655
+70,850
+5% +$26.7M 1.35% 16
2021
Q3
$611M Buy
1,481,805
+84,769
+6% +$35M 1.48% 10
2021
Q2
$517M Buy
1,397,036
+135,717
+11% +$50.2M 1.27% 19
2021
Q1
$366M Buy
1,261,319
+169,486
+16% +$49.1M 0.98% 30
2020
Q4
$273M Buy
1,091,833
+145,362
+15% +$36.3M 0.79% 45
2020
Q3
$214M Buy
946,471
+153,828
+19% +$34.8M 0.78% 42
2020
Q2
$138M Buy
792,643
+145,047
+22% +$25.3M 0.58% 52
2020
Q1
$81.7M Sell
647,596
-565,314
-47% -$71.3M 0.47% 62
2019
Q4
$185M Buy
1,212,910
+87,523
+8% +$13.4M 0.89% 32
2019
Q3
$149M Buy
1,125,387
+667,611
+146% +$88.4M 0.78% 38
2019
Q2
$65M Buy
457,776
+112,229
+32% +$15.9M 0.34% 74
2019
Q1
$50.2M Buy
345,547
+44,718
+15% +$6.5M 0.29% 82
2018
Q4
$34M Sell
300,829
-4,489
-1% -$508K 0.23% 90
2018
Q3
$41.1M Buy
+305,318
New +$41.1M 0.24% 90